The FDA has issued a nclick="javascript:window.open('https://www.fda.gov/media/166347/download', '_blank', 'noopener'); return false;">“no questions” letter to nclick="javascript:window.open('https://www.goodmeat.co/', '_blank', 'noopener'); return false;">GOOD Meat for the company’s cultivated chicken. The product has been available to consumers in Singapore since 2020.

GOOD Meat is the second cultivated meat company to go through the FDA’s pre-market review process – in November 2022, the nclick="javascript:window.open('https://www.fda.gov/food/cfsan-constituent-updates/fda-completes-first-pre-market-consultation-human-food-made-using-animal-cell-culture-technology', '_blank', 'noopener'); return false;">agency completed a pre-market review for UPSIDE Food’s cultivated chicken.

The pre-market consultation is just the first step in bringing cultivated meat to the U.S. market. Cultivated meat companies still have to meet most of the same regulatory requirements, including facility registration, food safety planning, and USDA inspection. In addition, the FDA and USDA are jointly developing labeling rules.

Jessica Almy, vice president of policy at the Good Food Institute (GFI), commented: “GFI celebrates the momentum we’ve seen from FDA over the last few months as they’ve given the greenlight to cultivated chicken from two innovative American companies. Consumers looking for ways to eat more sustainably will have more choices, and will soon be able to try the same delicious chicken that GOOD Meat has been serving in Singapore for the past two years without having to fly to another country. As governments around the world look for ways to address the climate and global health impacts of food production, clear and efficient regulatory review of cultivated meat is a significant step in the right direction.”